Forte Biosciences, Inc. (FBRX) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
3060 PEGASUS PARK DRIVE DALLAS, TX 75247 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
| 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 16,363,000 | 24,498,000 | 30,444,000 | 37,125,000 | 46,185,000 | 30,425,000 | |||
| Cash and cash equivalent | 16,363,000 | 24,498,000 | 30,444,000 | 37,125,000 | 46,185,000 | 20,438,000 | |||
| Short-term investments | 9,987,000 | ||||||||
| Other undisclosed cash, cash equivalents, and short-term investments | |||||||||
| Prepaid expense | 606,000 | 527,000 | 513,000 | 483,000 | 464,000 | 322,000 | |||
| Other undisclosed current assets | 699,000 | 686,000 | 545,000 | 719,000 | 453,000 | ||||
| Total current assets: | 17,668,000 | 25,711,000 | 31,502,000 | 38,327,000 | 47,102,000 | 30,747,000 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 86,000 | 96,000 | 106,000 | 109,000 | 98,000 | 30,000 | |||
| Other noncurrent assets | 192,000 | 271,000 | 409,000 | 544,000 | 679,000 | 407,000 | |||
| Total noncurrent assets: | 278,000 | 367,000 | 515,000 | 653,000 | 777,000 | 437,000 | |||
| TOTAL ASSETS: | 17,946,000 | 26,078,000 | 32,017,000 | 38,980,000 | 47,879,000 | 31,184,000 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 8,580,000 | 9,117,000 | 3,332,000 | 3,666,000 | 7,471,000 | 6,300,000 | |||
| Accounts payable | 5,159,000 | 5,275,000 | 1,685,000 | 1,424,000 | 5,354,000 | 3,006,000 | |||
| Accrued liabilities | 3,421,000 | 3,842,000 | 1,647,000 | 2,242,000 | 2,117,000 | 3,294,000 | |||
| Total current liabilities: | 8,580,000 | 9,117,000 | 3,332,000 | 3,666,000 | 7,471,000 | 6,300,000 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 8,580,000 | 9,117,000 | 3,332,000 | 3,666,000 | 7,471,000 | 6,300,000 | |||
| Equity | |||||||||
| Equity, attributable to parent | 9,366,000 | 16,961,000 | 28,685,000 | 35,314,000 | 40,408,000 | 24,884,000 | |||
| Common stock | 1,000 | 36,000 | 36,000 | 36,000 | 36,000 | 21,000 | |||
| Additional paid in capital | 156,207,000 | 155,383,000 | 154,591,000 | 153,794,000 | 153,025,000 | 127,555,000 | |||
| Accumulated other comprehensive income (loss) | 1,000 | (7,000) | (2,000) | 4,000 | (5,000) | 1,000 | |||
| Accumulated deficit | (146,843,000) | (138,451,000) | (125,940,000) | (118,520,000) | (112,648,000) | (102,693,000) | |||
| Total equity: | 9,366,000 | 16,961,000 | 28,685,000 | 35,314,000 | 40,408,000 | 24,884,000 | |||
| TOTAL LIABILITIES AND EQUITY: | 17,946,000 | 26,078,000 | 32,017,000 | 38,980,000 | 47,879,000 | 31,184,000 | |||
Income Statement (P&L) (USD)Annual | Quarterly
| 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (8,629,000) | (12,818,000) | (7,804,000) | (6,381,000) | (10,216,000) | (9,034,000) | ||
| Operating loss: | (8,629,000) | (12,818,000) | (7,804,000) | (6,381,000) | (10,216,000) | (9,034,000) | ||
| Nonoperating income (expense) (Other Nonoperating Income (Expense)) | 237,000 | 307,000 | 384,000 | (615,000) | 261,000 | 138,000 | ||
| Loss from continuing operations before equity method investments, income taxes: | (8,392,000) | (12,511,000) | (7,420,000) | (6,996,000) | (9,955,000) | (8,896,000) | ||
| Other undisclosed income from continuing operations before income taxes | ||||||||
| Net loss: | (8,392,000) | (12,511,000) | (7,420,000) | (6,996,000) | (9,955,000) | (8,896,000) | ||
| Other undisclosed net income attributable to parent | 1,124,000 | |||||||
| Net loss available to common stockholders, diluted: | (8,392,000) | (12,511,000) | (7,420,000) | (5,872,000) | (9,955,000) | (8,896,000) | ||
Comprehensive Income (USD)Annual | Quarterly
| 12/31/2024 Q4 | 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (8,392,000) | (12,511,000) | (7,420,000) | (6,996,000) | (9,955,000) | (8,896,000) | ||
| Comprehensive loss: | (8,392,000) | (12,511,000) | (7,420,000) | (6,996,000) | (9,955,000) | (8,896,000) | ||
| Other undisclosed comprehensive income (loss), net of tax, attributable to parent | 8,000 | (5,000) | (6,000) | 1,133,000 | (6,000) | 1,000 | ||
| Comprehensive loss, net of tax, attributable to parent: | (8,384,000) | (12,516,000) | (7,426,000) | (5,863,000) | (9,961,000) | (8,895,000) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.